FDA Approves First Injectable Treatment for HIV Pre-Exposure …
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms...
What Is Injectable HIV PrEP? The US Food and Drug Administration (FDA) has approved one injectable pre-exposure prophylaxis (PrEP) medication: cabotegravir (CAB) 600 mg (brand name Apretude®). CAB is a single antiretroviral drug given as an intramuscular injection every 2 months to prevent HIV.
FDA Approves First Injectable Treatment for HIV Pre-Exposure …
[On December 20, 2021], the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.
Pre-Exposure Prophylaxis - HIV.gov
Jun 27, 2024 · PrEP, or pre-exposure prophylaxis, is medicine people at risk for HIV take to prevent getting HIV from sex or injection drug use. PrEP can stop HIV from taking hold and spreading throughout your body.
Clinical Guidance for PrEP | HIV Nexus | CDC - Centers for Disease ...
Aug 20, 2024 · PrEP (pre-exposure prophylaxis) is the use of antiretroviral medication to prevent HIV. PrEP is for people without HIV who may be exposed to HIV through sex or injection drug use.
Pre-Exposure Prophylaxis (PrEP) | HIV Risk and Prevention - CDC
Pre-exposure prophylaxis (or PrEP) is medicine taken to prevent getting HIV. PrEP is highly effective for preventing HIV when taken as prescribed. PrEP reduces the risk of getting HIV from sex by about 99%. PrEP reduces the risk of getting HIV from injection drug use by at least 74%.
Long-acting PrEP | APRETUDE (cabotegravir)
APRETUDE, long-acting injectable PrEP for HIV-1–negative at-risk adults & adolescents weighing at least 77 lbs. See Prescribing Info & Boxed Warning. Find more information about APRETUDE.
Apretude (HIV PrEP) Uses, Dosage, Side Effects - Drugs.com
Jun 20, 2024 · Apretude (cabotegravir) extended-release injection is a long-acting pre-exposure prophylaxis (PrEP) prescription medicine used to prevent HIV infection in people at risk for sexually-acquired HIV exposure.
FDA approves first injectable PrEP medication to lower HIV risk
Dec 20, 2021 · The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday.
On December 20, 2021, the U.S Food and Drug Administration approved Apretude® (cabotegravir extended-release injectable suspension) for PrEP, making it the first LAI medication option available for the primary prevention of HIV. Apretude® is indicated for adults and adolescents weighing at least 77 pounds who are at risk of sexually acquiring ...